Kyntra Bio (MEX:KYNB) Total Operating Expense: MXN866.2 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:KYNB Kyntra Bio Inc MEX:KYNB
35 GF Score
Price MXN127.90
GF Value MXN98.73
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Kyntra Bio Total Operating Expense?

Kyntra Bio MEX:KYNB 35 Total Operating Expense is MXN866.2 Mil as of Mar. 2026. GuruFocus rates MEX:KYNB with a GF Score™ of 35/100 and a GF Value™ of MXN98.73 (Modestly Overvalued). The stock has 8 warning signs investors should review.

Kyntra Bio's Total Operating Expense for the three months ended in Mar. 2026 was MXN242.1 Mil. Kyntra Bio's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was MXN866.2 Mil.

Kyntra Bio Total Operating Expense Related Terms

Kyntra Bio Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Kyntra Bio's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kyntra Bio Total Operating Expense Chart

Kyntra Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10,482.00 8,217.15 5,991.16 3,024.54 922.36

Kyntra Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 353.54 243.31 119.31 261.41 242.14
MEX:KYNB
35GF Score
Kyntra Bio Inc MEX:KYNB
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kyntra Bio Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN866.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of MXN866.2 Mil mean?
Kyntra Bio (MEX:KYNB) has a Total Operating Expense of MXN866.2 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Kyntra Bio and its competitors.
Is Kyntra Bio's Total Operating Expense too high?
Kyntra Bio's current Total Operating Expense is MXN866.2 Mil. Overall, Kyntra Bio has a GF Score™ of 35/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kyntra Bio's Total Operating Expense compare to TVGN and PSTV?
Kyntra Bio's Total Operating Expense of MXN866.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Kyntra Bio and its competitors. Kyntra Bio's current Total Operating Expense is MXN866.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyntra Bio stock overvalued right now?
Based on GuruFocus' analysis, Kyntra Bio (MEX:KYNB) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN98.73, compared to a current price of MXN127.90 — trading 29.5% above its estimated fair value. The current Total Operating Expense is MXN866.2 Mil. Kyntra Bio's overall GF Score™ is 35/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Kyntra Bio (MEX:KYNB), the current Total Operating Expense is MXN866.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kyntra Bio (MEX:KYNB) Overvalued in 2026?

Based on GuruFocus' analysis, Kyntra Bio stock appears to be overvalued. The current stock price of MXN127.90 is trading 29.5% above its estimated GF Value™ of MXN98.73. GuruFocus considers Kyntra Bio to be Modestly Overvalued.

Key valuation signals for MEX:KYNB:

  • Total Operating Expense: MXN866.2 Mil
  • GF Value™: MXN98.73 vs. price of MXN127.90 (29.5% above fair value)
  • GF Score™: 35/100 with 8 warning signs

No single metric tells the full story. See the MEX:KYNB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kyntra Bio Business Description

Other Exchanges KYNB:USA0IL8:UK1FG0:Germany
Address 350 Bay Street, Suite 100, No. 6009, San Francisco, CA, USA, 94133
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
35GF Score

Get the complete analysis for MEX:KYNB

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN127.90
Price
MXN98.73
GF Value